Stock Quote
Cepheid (CPHD.O) (Nasdaq)
$13.57
3:14pm EST
+1.50%
$13.37
$13.50
317,430
$13.81
$13.27
$15.98
$4.93
1.43
260,194
CPHD.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Gutshall, Thomas | Chairman of the Board | 142,198 |
| Bishop, John | Chief Executive Officer, Director | 1,459,010 |
| Miller, Andrew | Chief Financial Officer, Senior Vice President | 744,463 |
Profile
Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the biothreat and industrial markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases... Full Description
Company Address
Cepheid
904 Caribbean Drive
Sunnyvale CA 94089
P: +1408.5414191
F: +1408.5414192
904 Caribbean Drive
Sunnyvale CA 94089
P: +1408.5414191
F: +1408.5414192
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Invitrogen Corporation | $49.81 | +0.33 |
| Roche Holding Ltd. | CHF166.20 | +3.50 |
| Roche Holding Ltd. | CHF169.10 | +1.80 |
| CPHD.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 7.62 |
| P/S(TTM) | 4.92 | 0.46 |
| ROI(TTM) | -18.18 | 0.98 |
| ROE(TTM) | -19.01 | 1.52 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.10 |
| EPS Est. (Current Year) | -0.42 |
| Total Revenue | $41.63M |
| Net Income | $-3.84M |
| EPS | $-0.07 |
